A 3-ketosteroid delta1-dehydrogenase mutant and its use in the production of steroid drug intermediates
By molecularly modifying KstD2 and optimizing reaction conditions, a 3-sterone-Δ1-dehydrogenase mutant, KstD2/V156P/V165I, with high catalytic activity was obtained, solving the problem of low catalytic activity of KstD2 and realizing the industrial production of 6-methylglycates with high efficiency.
Patent Information
- Application Number
- CN202611344316.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-01
- Publication Date
- 2026-11-10
AI Technical Summary
The existing 3-sterone-Δ1-dehydrogenase KstD2 has low catalytic activity, making it difficult to efficiently convert 6α-methyl-11β,17α-dihydroxy-4-pregnen-3,20-dione (6-methylglycate), which cannot meet the needs of industrial production.
By rationally designing and modifying KstD2, a 3-sterone-Δ1-dehydrogenase mutant, KstD2/V156P/V165I, was obtained. Combined with a methanol-PBS system, the catalytic activity and reaction stability were improved.
The mutant KstD2/V156P/V165I achieved a conversion rate of 98.37% under high substrate feed rates, significantly improving catalytic efficiency and making it suitable for industrial biocatalytic conversion.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
(I) Technical Field
[0001] This invention relates to a mutant of 3-sterone-Δ1-dehydrogenase and its application in the production of steroidal drug intermediates. (II) Background Technology
[0002] Steroids, also known as steroids, are a class of terpenoid lipid molecules with a cyclopentane-polyhydrophenanthrene core. Due to the differences in the type, position, number, and stereoconfiguration of their substituents, steroids possess a rich variety of chemical properties and physiological activities, making them indispensable exogenous hormone drugs in clinical practice. Steroid drugs are widely used in anti-inflammatory, immunosuppressive, contraceptive, endocrine regulation, and anti-tumor applications, and are the second largest class of clinical drugs after antibiotics. They are mainly divided into three categories: adrenocortical hormones, sex hormones, and anabolic steroids, occupying an important position in the chemical drug system.
[0003] Most steroidal drugs are derived from natural products with a steroidal skeleton through structural modification. The industrial production of steroidal drugs mainly involves two methods: chemical synthesis and microbial transformation. Preparing important intermediates for drugs using chemical methods presents numerous problems, including high production costs, long synthetic routes, difficulties in handling byproducts, and significant environmental pollution. Microbial transformation, on the other hand, utilizes specific enzymes to catalyze substrates, converting them into higher-value products. This process is essentially enzymatic catalysis, exhibiting high specificity and chiral selectivity, and can effectively address the problems currently existing in chemical synthesis.
[0004] 6α-Methyl-11β,17α-dihydroxy-4-pregnen-3,20-dione (abbreviated as 6-methylgerset) is a white powdery solid, sparingly soluble in water, but readily soluble in organic solvents such as methanol, acetone, and dichloromethane. It is often used as a key intermediate in the synthesis of methylprednisolone. 3-Sterone-Δ 1 -Dehydrogenase (3-ketosteroid-Δ) 1 -dehydroge, EC: 1.3.99.4, abbreviated as Δ 1 KstD is an important flavin adenine dinucleotide (FAD)-dependent oxidoreductase that catalyzes the trans-axial elimination reaction of hydrogen atoms at the C1 (α) and C2 (β) positions in 3-ketosteroids, introducing a double bond between the C1 and C2 positions of the steroid nucleus. KstD2 is derived from *Mycobacterium virginianum* (…). Mycobacterium neoaurum 3-Sterone-Δ in DSM 1381 1KstD2 dehydrogenase, containing 557 amino acids, possesses a flexible active pocket and broad substrate applicability, enabling it to bind to various 3-ketosteroid substrates to complete catalytic reactions. However, it exhibits low catalytic activity and insufficient conversion efficiency for 6-methyl steroids, failing to meet the demands for efficient 6-methyl steroid preparation in industrial production. Therefore, the industry urgently needs to obtain a KstD2 mutant with higher catalytic activity for this substrate. (III) Summary of the Invention
[0005] The purpose of this invention is to provide a 3-sterone-Δ1-dehydrogenase mutant and its application in the production of steroid drug intermediates by catalyzing the dehydrogenation of steroid drugs at the C1 and C2 positions. This invention systematically modifies the KstD2 enzyme through a rational design method to obtain a mutant with high catalytic dehydrogenation ability for 6α-methyl-11β,17α-dihydroxy-4-pregnen-3,20-dione, effectively improving catalytic activity and reaction stability, and achieving low-energy consumption, green and mild catalytic production.
[0006] The technical solution adopted in this invention is: In a first aspect, the present invention provides a 3-sterone-Δ1-dehydrogenase mutant, which is obtained by single or multiple mutations at position 156 or 165 of the amino acid sequence shown in SEQ ID NO: 1.
[0007] Furthermore, the 3-sterone-Δ1-dehydrogenase mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO: 1 to one of the following: V156P, V165I, or V156P / V165I, wherein the amino acid sequence of V156P / V165I is shown in SEQ ID NO: 3.
[0008] The 3-sterone-Δ1-dehydrogenase mutant described in this invention is derived from Mycobacterium virginianum (… Mycobacterium neoaurum The 3-sterone-Δ1-dehydrogenase KstD2 in DSM 1381 was obtained through rational design, and the amino acid sequence of the 3-sterone-Δ1-dehydrogenase is shown in SEQ ID NO: 1.
[0009] Secondly, the present invention provides a recombinant expression vector for expressing the coding gene of a 3-sterone-Δ1-dehydrogenase mutant and a recombinant genetically engineered bacterium. The recombinant expression vector is based on plasmid pET-28a(+), and the recombinant genetically engineered bacterium uses Escherichia coli BL21(DE3) as the host bacterium.
[0010] Thirdly, the present invention provides an application of a 3-sterone-Δ1-dehydrogenase mutant in the production of steroidal drug intermediates, wherein the application is to catalyze the dehydrogenation of the substrate 6α-methyl-11β,17α-dihydroxy-4-pregnen-3,20-dione (hereinafter referred to as 6-methyl dehydrogenase) to synthesize 6α-methyl-11β,17α-dihydroxy-1,4-dipregnen-3,20-dione (hereinafter referred to as 6-methyl dehydrogenase).
[0011] Furthermore, the method of application is as follows: using wet bacterial cells obtained by inducing culture of recombinant genetically engineered bacteria containing the encoding gene of 3-sterone-Δ1-dehydrogenase, or crude enzyme solution extracted by ultrasonic disruption of the wet bacterial cells, as a catalyst, using 6-methyl dehydrogenase as a substrate, phenazine sulfate methyl ester (PMS) as a proton acceptor, flavin adenine dinucleotide (FAD) as a coenzyme, adding methanol as a cosolvent, and using a buffer solution of pH 6-8 (preferably pH 7.0) as a reaction medium to construct a reaction system, and reacting at 25-45 ℃ and 100-200 rpm for 48-120 h (preferably 40 ℃, 180 rpm, 72 h) to obtain the 6-methyl dehydrogenase.
[0012] Furthermore, in the conversion system, the substrate concentration is 20-60 g / L (preferably 30 g / L); the final concentration of PMS is 0.5-2.5 mM (preferably 1 mM); the final concentration of FAD is 0.2 mM; the concentration of wet cells is 30-60 g / L (preferably 50 g / L); and the volume percentage of methanol added is 4-5%.
[0013] Furthermore, the buffer solution is a 50 mM, pH 7.0 PBS buffer solution.
[0014] Furthermore, the wet bacterial cells are prepared as follows: recombinant genetically engineered bacteria containing the gene encoding the 3-sterone-Δ1-dehydrogenase mutant are inoculated into a solution containing 50... The seed culture was obtained by incubating the LB liquid medium containing 3 g / mL kanamycin sulfate at 37 °C and 180 rpm overnight. The seed culture was then inoculated at a volume concentration of 3% into a culture medium containing 50 g / mL kanamycin sulfate. In TB liquid medium containing g / mL kanamycin sulfate, cultured at 37 ℃ and 180 rpm until OD 600 The concentration of the culture medium was 0.6-0.8. IPTG was added to a final concentration of 0.2 mM, and the culture was induced at 20℃ and 180 rpm for 16 h to obtain the fermentation broth. The fermentation broth was centrifuged at 8000 rpm and 4℃ for 10 min. The resulting bacterial precipitate was resuspended twice in physiological saline and then centrifuged at 8000 rpm and 4℃ for 10 min to collect the wet bacterial cells. The wet bacterial cells were resuspended in 50 mM PBS buffer (pH 7.0) at a concentration of 50 g / L. The resuspended solution was placed on ice for 30 min and then sonicated (conditions: sonication power 360 W, sonication for 3 s, interval 7 s, sonication for 15 min). The sonicated solution was centrifuged at 8000 rpm and 4 ℃ for 10 min and the precipitate was discarded. The resulting supernatant was the crude enzyme solution.
[0015] Compared with the prior art, the beneficial effects of the present invention are mainly reflected in: This invention, through the source Mycobacterium neoaurum Computer-aided protein design and enzyme-substrate binding pocket-guided engineering of the 3-sterone-Δ1-dehydrogenase KstD2 in DSM 1381 were carried out, with only two rounds of site-directed saturation mutagenesis conducted. This resulted in the screening of mutants with high catalytic activity for 6-methylglycates from wild-type KstD2.
[0016] The mutant KstD2 / V156P / V165I of this invention can still achieve a conversion rate of 98.37% under a high substrate feed rate of 40 g / L, indicating that the mutant has excellent substrate tolerance and catalytic efficiency, providing a candidate enzyme with practical value for the industrial biocatalytic conversion of 6-methylglycans.
[0017] 6-Methylglucan is poorly soluble in water, which significantly reduces the efficiency of dehydrogenation compound formation. To address the common industry challenge of poor water solubility and low mass transfer of steroid substrates in aqueous phases, this invention employs a methanol-PBS system to increase substrate solubility and thus improve biocatalytic efficiency. The mutant KstD2 / V156P / V165I showed a conversion efficiency of only 60.18% for a 40 g / L 6-methylglucan feed in a single-phase aqueous system (PBS buffer) without methanol. However, under the same conditions, the conversion rate increased to 98.37% in the PBS buffer system with added methanol. This methanol addition strategy is simple to operate, low in cost, and more suitable for industrial-scale applications. (iv) Description of the attached drawings
[0018] Figure 1 A schematic diagram of the synthesis of 6-methyl dehydrogenates from 6-methyl Grignard substrates catalyzed by KstD2.
[0019] Figure 2 This diagram shows the distribution of amino acid sites within 5 Å in the docking structure of KstD2 with the substrate 6-methylglycate.
[0020] Figure 3 This is an electrophoresis diagram of nucleic acid from PCR amplification products; where Lane 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 represent randomly selected PCR products.
[0021] Figure 4 The results show the relative enzyme activity of KstD2 and its V156 and V165 mutants.
[0022] Figure 5 The results show the relative enzyme activity of the combined mutants constructed based on the dominant single mutants V156A, V156K, V156P, V165I, and V165W.
[0023] Figure 6 The HPLC chromatogram shows the dehydrogenation of 6-methylglucan catalyzed by the dominant mutant KstD2 / V156P / V165I.
[0024] Figure 7 The results show the effects of different concentrations of PMS and DCPIP on the substrate conversion ability of KstD2 / V156P / V165I.
[0025] Figure 8 The results show the effect of different pH conditions on the substrate conversion capacity of KstD2 / V156P / V165I.
[0026] Figure 9 The results show the effects of different substrate concentrations and reaction times on the substrate conversion capacity of KstD2 / V156P / V165I.
[0027] Figure 10 The results show the effects of wild-type strain KstD2 and mutant KstD2 / V156P / V165I on the substrate transformation process. (V) Detailed Implementation Methods
[0028] The present invention will be further described below with reference to specific embodiments, but the scope of protection of the present invention is not limited thereto: The culture medium used in the embodiments of this invention consists of: The composition of LB liquid medium is: NaCl 10 g / L, peptone 10 g / L, yeast extract 5 g / L, water as solvent, pH 7.0.
[0029] The composition of LB solid medium is: NaCl 10 g / L, peptone 10 g / L, yeast extract 5 g / L, agar 20 g / L, water as solvent, pH 7.0.
[0030] TB culture medium composition: tryptone 11.8 g / L, yeast extract 23.6 g / L, K2HPO4 9.4 g / L, KH2PO4 2.2 g / L, glycerol 4 mL / L, solvent is water.
[0031] The PBS buffer used in the embodiments of this invention refers to 50 mM, pH 7.0 phosphate buffer.
[0032] Unless otherwise specified, the solvent for the solutions in the embodiments of the present invention is double-distilled water.
[0033] Example 1: Construction of a 3-sterone-Δ1-dehydrogenase mutant library
[0034] 1. Screening of wild-type 3-sterone-Δ1-dehydrogenase and construction of recombinant genetically engineered strains
[0035] (1) Obtaining the target gene of 3-sterone-Δ1-dehydrogenase KstD2
[0036] To screen for suitable 3-sterone-Δ1-dehydrogenases, a literature review was conducted, selecting 3-sterone-Δ1-dehydrogenases with high catalytic potential for 6-methyl Grignard compounds and good enzyme stability. Further searches were performed in the NCBI database, selecting those derived from *Mycobacterium neogenes* (…). Mycolicibacterium neoaurum The gene sequence of 3-sterone-Δ1-dehydrogenase KstD2 of DSM 1381 (Genbank: MG251736.1) was obtained and the gene sequence was synthesized by the Hangzhou branch of Beijing Qingke Biotechnology Co., Ltd. The amino acid sequence is shown in SEQ ID NO: 1. A His-tag was introduced at the end of the synthesized gene.
[0037] SEQ ID NO: 1
[0038] .
[0039] (2) Synthesis of recombinant plasmid pET-28a(+)-KstD2
[0040] The Hangzhou branch of Beijing Qingke Biotechnology Co., Ltd. was commissioned to insert the KstD2 target gene into the expression vector pET-28a(+). Hind III and BmaH I. Two restriction enzyme sites were used to obtain the recombinant plasmid pET-28a(+)-KstD2.
[0041] (3) Construction of recombinant genetically engineered bacteria
[0042] The recombinant plasmid pET-28a(+)-KstD2 was transformed into... E. coli BL21(DE3) competent cells, the specific method is as follows: E. coli BL21(DE3) competent cells were placed on ice for 30 min to allow them to thaw completely; then, 10 μL of the cells were aspirated into a clean bench. The L recombinant plasmid was slowly added to 100... In L competent bacterial culture, gently mix by pipetting, incubate on ice for 20 min, then precisely heat shock in a 42 ℃ water bath for 90 s, followed by an ice bath for 2 min. Add 900 µL of antibiotic-free LB liquid medium and incubate at 37 ℃ and 180 rpm for 1 h. Centrifuge the incubated bacterial culture, discard 900 µL of supernatant, and mix the remaining 100 µL of bacterial culture with the precipitate by pipetting. Spread the mixture onto LB solid medium containing 50 μg / mL kanamycin sulfate and incubate overnight at 37 ℃.
[0043] Single colonies were randomly selected from overnight culture plates and inoculated into LB liquid medium containing 50 μg / mL kanamycin sulfate. The cultures were incubated overnight at 37 °C and 180 rpm. Positive clones were obtained by 0.9% nucleic acid agarose gel electrophoresis. The plasmid pET-28a(+)-KstD2 was extracted using an E. coli plasmid extraction kit and stored at -80 °C.
[0044] 2. Screening for mutation sites
[0045] The three-dimensional structure of the KstD2 protein was predicted using AlphaFold 3. Molecular docking simulations of KstD2 and its substrate 6-methylglycate (abbreviated as S) were performed using AutoDock Vina software to construct a structural model of the KstD2-FAD-S complex. Key amino acid residues binding to the substrate were analyzed and identified within the catalytic pocket and substrate channel regions (see [link to relevant documentation]). Figure 2 The docking process followed the AutoDock user guide, selecting FAD and 6-methylglycine as flexible ligands and KstD2 protein as a rigid acceptor. The docking region was set at the substrate binding site within the substrate inlet / outlet pouch. Docking was performed in two steps: first, KstD2 was docked with FAD, and the result was output as a PDB file; second, docking was performed using the docked KstD2-FAD as the rigid acceptor and 6-methylglycine as the flexible ligand. Preliminary analysis was performed after docking, and the docking conformation with the substrate C1,2 position close to the isorhexidine ring of FAD was selected as the optimal conformation, and the result was output as a KstD2-FAD-S.PDB file. PyMol was used to visualize and analyze the PDB file, and the optimized results were output as PNG images.
[0046] Rational analysis of the docked molecular structure was conducted, selecting 32 amino acid residues within a 5 Å range of the substrate active pocket. FireProt software was used to perform a comprehensive amino acid substitution scan on these residues, ultimately identifying two candidate mutation sites: Val156 and Val165. Subsequent steps will involve constructing a mutant library through site-directed saturation mutagenesis to further screen for mutants with the highest catalytic activity.
[0047] 3. Single-point mutation
[0048] (1) Plasmid extraction
[0049] The plasmid pET-28a(+)-KstD2 was extracted from the recombinant genetically engineered bacteria constructed in step 1 using the Takara UE plasmid mini-preparation kit and used as a template for subsequent PCR or for transformation.
[0050] (2) Primer design
[0051] Based on the two candidate sites, Val156 and Val165, identified through FireProt virtual screening in step 2, saturation mutation primers were designed. The primers used the degenerate codon NNK to cover all 20 amino acid substitutions, namely Val156(V)-F, Val156(V)-R, Val165(V)-F, and Val165(V)-R (sequences shown in Table 1). Using pET-28a(+)-KstD2 plasmid as a template, plasmid PCR was performed using the PrimeSTAR MaxPremix (2×) enzyme from Takara's Prime STAR Max DNA Ploymerase (catalog number: R045A). A mutant library was constructed using single-point mutagenesis technology, and mutants with enhanced catalytic activity were further screened.
[0052] Table 1: Primer sequences
[0053] Note: The underlined part is the mutation site, M represents C / A, N represents A / C / T / G, and K represents T / G.
[0054] (3) PCR amplification
[0055] PCR amplification system: template 0.5-20 ng, 10 µL PrimeSTAR Max Premix (2×), 0.5 µL each of upstream and downstream mutant primers, and ddH2O to a final volume of 20 µL.
[0056] PCR reaction conditions: 94 ℃ pre-denaturation for 2 min; 98 ℃ denaturation for 10 s, 57 ℃ annealing for 15 s, 72 ℃ extension for 1 min, for a total of 35 cycles; 72 ℃ final extension for 10 min; store at 4 ℃.
[0057] (4) Transformation of positive clones
[0058] After amplification, 10 PCR products were randomly selected, and a small amount was analyzed by agarose gel electrophoresis. The results are shown below. Figure 3 If the size of the target band is consistent with that of the whole plasmid, it indicates that the PCR amplification was successful.
[0059] Take 8.5 µL of PCR product, add 0.5 µL of restriction endonuclease Dpn I and 1 µL of 10×T buffer, and digest at 37℃ for 30 min to remove template DNA. Transform 10 µL of the deionized product. Ecoli BL21(DE3) competent cells were evenly spread on LB solid medium containing 50 mg / L kanamycin sulfate and cultured overnight at 37 °C.
[0060] Single transformants were selected and inoculated into 96-well plates containing 600 µL LB liquid medium (containing 50 mg / L kanamycin sulfate) and incubated at 37 ℃ and 180 rpm for 12 h. The seed culture was then transferred to 96-well plates containing an equal volume of fresh medium using a 96-well sample replicator. This transfer was repeated three times for expansion culture. The culture was allowed to grow until the OD of the bacterial culture was reached. 600 After reaching a concentration of 0.6–0.8, IPTG was added to a final concentration of 0.2 mM, and expression was induced at 20 ℃ for 16 h. After culture, the 96-well deep-well plates were centrifuged at 5000 rpm and 4 ℃ for 10 min, and the supernatant was discarded. The bacterial cells in each well were resuspended in 600 µL of 2 mg / mL lysozyme solution (prepared with 0.1 mM, pH 7.0 PBS buffer) and incubated at 30 ℃ for 2 h to lyse the bacterial cells. Subsequently, the plates were centrifuged again at 5000 rpm and 4 ℃ for 10 min to remove the crude cell extract, and the supernatant was collected as the crude enzyme solution.
[0061] (5) Screening for single mutants
[0062] In a 50 mM PBS buffer solution at pH 7.0 with a total volume of 100 µL, the following components were added sequentially to final concentrations: 20 mM 6-methylglycate substrate (pre-dissolved in methanol to achieve a final methanol volume fraction of 4%), 5 mM electron acceptor 2,6-dichlorobenzylindolephenol (DCPIP), 15 mM electron mediator phenazine methyl sulfate (PMS), and 5 µL of the crude enzyme solution prepared in step (4). Enzyme activity was determined using the method described in Example 2, and the results are shown in [Figure 2]. Figure 4 Transformants with high activity were selected for sequencing to obtain single mutants.
[0063] The substrate conversion rate was then detected using the method described in Example 2 for further screening, and the dominant single mutants KstD2-V156A, KstD2-V156K, KstD2-V156P, KstD2-V165I, and KstD2-V165W were finally obtained.
[0064] 4. Screening of combined mutants
[0065] Based on the single-point screening in step 3, pairwise iterative mutations were performed using the primers in Table 2, the PCR amplification system and conditions in step 3. Initial screening of the strains was conducted using enzyme activity assays, and single colonies were selected for sequencing analysis. The relative enzyme activity (with wild-type KstD2 as 100%) of the initial screening of the combined mutants is shown in the figure below. Figure 5 As shown; based on this, a biotransformation reaction is carried out, and the conversion rates of different combinations of mutants during the catalytic substrate reaction are compared to determine the optimal combination of mutants.
[0066] The final screening yielded the following dominant mutants: KstD2 / V156A / V165I, KstD2 / V156A / V165W, KstD2 / V156K / V165I, KstD2 / V156K / V165W, KstD2 / V156P / V165I, and KstD2 / V156P / V165W.
[0067] The HPLC chromatogram of the optimal mutant KstD2 / V156P / V165I catalyzing the conversion of the substrate 6-methyl Grignard is shown in the figure. Figure 6 Its conversion rate was 98.37%, named KstD2-M, with the nucleotide sequence shown in SEQ ID NO: 2 and the amino acid sequence shown in SEQ ID NO: 3. The corresponding recombinant genetically engineered bacteria is... E. coli BL21(DE3)-pET-28a(+)-KstD2-M.
[0068] Table 2: Primer sequences
[0069] SEQ ID NO: 3
[0070] .
[0071] Example 2: Detection of enzyme activity and substrate conversion rate of wild-type 3-sterone-Δ1-dehydrogenase and its mutants
[0072] 1. Enzyme activity detection
[0073] The DCPIP method was used to determine the enzyme activity of KstD2 and its mutants. The principle of the assay is as follows: KstD2 enzyme catalyzes the dehydrogenation of the substrate, and DCPIP is reduced by hydrogen transfer via PMS. DCPIP has a characteristic absorption peak at 600 nm. The reduction rate of DCPIP can be calculated by measuring the change in absorbance, thereby characterizing the enzyme activity of KstD2.
[0074] The KstD2 enzyme activity assay system consisted of the following components: 5 mM 6-methylglycine substrate, 5% methanol (v / v), 2 mM DCPIP, 15 mM PMS, and an appropriate amount of crude enzyme solution, which was then brought to a final volume of 200 µL with 50 mM PBS buffer (pH 7.0). The reaction system was incubated at 30 °C for 30 min, and the absorbance at 600 nm was measured using a spectrophotometer. The concentration of DCPIP in the reaction solution was calculated based on the standard curve of DCPIP standard concentration versus absorbance. The relative enzyme activity was calculated with the wild-type strain's enzyme activity as 100%.
[0075] 2. Substrate conversion rate detection
[0076] The obtained mutants were used to prepare wet bacterial cells as catalysts in the method of Example 3, and the reaction was carried out with the substrate. The best dominant mutants were screened by liquid chromatography analysis.
[0077] The 5 mL reaction system consisted of: 20 g / L wet bacterial cells, 1 mM PMS, 30 g / L 6-methylglycine substrate, 0.2 mM FAD, 5% (v / v) methanol, and 50 mM PBS buffer (pH 7.0) to a final volume of 5 mL. The reaction was carried out at 37 °C and 180 rpm for 72 h in a shaker. After the conversion reaction was complete, the reaction solution was extracted three times with equal volumes of ethyl acetate, and the organic phase was collected. 1 mL of the organic phase was evaporated to dryness in a fume hood, and then redissolved in 500 µL of acetonitrile. The redissolved solution was filtered through a 0.45 µm organic microporous membrane, and 200 µL was collected in the inner liner of a liquid chromatography tube. High-performance liquid chromatography (HPLC) was used to detect the peak areas of the substrate and product, and the substrate conversion rate was calculated.
[0078] The concentrations of substrates and products were determined using an Agilent Technologies 1260 Infinity II high-performance liquid chromatograph equipped with a C18 column (Ultimate, 5 μm, 250 mm × 4.6 mm), a column temperature of 30 ℃, and a 245 nm UV detector. The mobile phase was acetonitrile:1% glacial acetic acid water at a volume ratio of 40:60, the flow rate was 1.3 mL / min, and the injection volume was 10 μL. The chromatographic peaks at retention times of 12.025 min and 13.289 min were the 6-methyl dehydrogenase product and the 6-methyl Grignard substrate, respectively.
[0079] Example 3: Preparation of crude enzyme solution from engineered bacteria
[0080] (1) Fermentation culture
[0081] The wild-type strain and mutant engineered bacteria constructed in Example 1 were taken out of the -80℃ freezer. E. coliBL21(DE3)-pET-28a(+)-KstD2-M was streaked onto LB agar plates containing 50 mg / L kanamycin sulfate and incubated at 37°C. After colony growth, a single colony was picked and inoculated into 5 mL of LB liquid medium containing 50 mg / L kanamycin sulfate and incubated at 30°C and 180 rpm for 12 h. The culture was then transferred at a 3% (v / v) inoculum to 100 mL of TB liquid medium containing 50 mg / L kanamycin sulfate. Initial OD... 600 The value was 0.2, and the cells were incubated at 37 ℃ and 180 rpm for 1.5–2 h. OD was then calculated. 600 When the concentration reaches 0.6–0.8, the culture flask is cooled, and IPTG is added to a final concentration of 0.2 mM. The culture is then induced at 20 °C and 180 rpm for 16 h to obtain the fermentation broth. The fermentation broth is centrifuged at 8000 rpm and 4 °C for 10 min. The resulting bacterial pellet is resuspended in physiological saline and centrifuged at 8000 rpm and 4 °C for 10 min to collect the wet bacterial cells, which are the resting cells.
[0082] (2) Crude enzyme solution
[0083] Step (1) The wet bacterial cells were resuspended in 50 mM PBS buffer (pH 7.0) at a concentration of 50 g / L. After the resuspended cells were placed on ice for 30 min, they were sonicated (conditions: sonication power 360 W, sonication for 3 s, interval 7 s, sonication for 15 min). The sonicated lysate was centrifuged at 8000 rpm and 4 ℃ for 10 min and the precipitate was discarded. The supernatant obtained was the crude enzyme solution, which was used for enzyme activity determination.
[0084] Example 4: Optimization of KstD2-M-catalyzed dehydrogenation conditions for 6-methyl Grignard compounds
[0085] The following conversion reactions were carried out using the KstD2-M wet cells prepared in Example 3 as catalysts. All substrates were first dissolved in methanol before being added.
[0086] 1. The effects of DCPIP and PMS as electron acceptors
[0087] To evaluate the effect of different electron acceptors on the catalytic activity of KstD2-M, the conversion rate of the substrate 6-methylglycine was determined in reaction systems containing different concentrations of PMS or DCPIP.
[0088] The final concentration of the 5 mL reaction system was: 0.2 mM FAD, 5% (v / v) methanol, 30 g / L substrate, 50 g / L KstD2-M wet cells prepared in Example 3, different concentrations (0, 0.5, 1, 1.5, 2, 2.5 mM) of PMS or DCPIP, and 50 mM PBS (pH 7.0) to a final volume of 5 mL. The mixture was incubated at 40 °C and 180 rpm for 72 h. The substrate conversion rate was then measured according to the method in Example 2. The results are as follows: Figure 7 As shown in the figure. Experimental results indicate that the dehydrogenation reaction of the substrate 6-methylglycate can proceed efficiently in the presence of PMS, and PMS is a better electron acceptor than DCPIP.
[0089] 2. The effect of pH on the dehydrogenation reaction
[0090] The catalytic activity of KstD2-M was detected at different pH values to investigate the effect of different pH values on the activity of KstD2-M.
[0091] The final concentration of the 5 mL reaction system consisted of: 50 g / L KstD2-M wet cells prepared in Example 3, 1 mM PMS, 30 g / L substrate 6-methylglycine, 0.2 mM FAD, 5% (v / v) methanol, and 50 mM buffer solutions at different pH levels (6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0) to a final volume of 5 mL. pH values 6.0, 6.5, 7.0, and 7.5 were 50 mM PBS; pH values 8.0, 8.5, and 9.0 were 50 mM Tris-HCl; and pH values 9.0, 9.5, and 10.0 were 25 mM glycine-NaOH buffer. The reaction was carried out at 40 °C and 180 rpm for 72 h. The substrate conversion rate was determined using the method described in Example 2, and the results are shown in [Figure 1]. Figure 8 .
[0092] like Figure 8 As shown, KstD2-M exhibits the highest activity at pH 7.0. pH changes alter the charge state of key amino acid residues in substrate molecules and the enzyme's active site, thus affecting the enzyme-substrate binding efficiency and the catalytic reaction process. Extreme pH conditions, whether too acidic or too alkaline, can disrupt non-covalent bonds (such as hydrogen bonds and ionic bonds) that maintain the higher-order structure of enzyme molecules, leading to unfolding, conformational changes, or even irreversible denaturation and inactivation of the enzyme protein. Therefore, KstD2-M is best suited for reaction in PBS buffer at pH 7.0.
[0093] 3. Effects of substrate concentration and reaction time on dehydrogenation reaction
[0094] To meet the needs of industrial production, it is necessary to maximize the substrate concentration in the reaction system while ensuring product yield and high enantioselectivity. Therefore, a reaction was designed to investigate the product conversion rate at different substrate concentrations.
[0095] The final concentration of the 5 mL reaction system consisted of: 50 g / L KstD2-M wet cells prepared in Example 3, 1 mM PMS, different concentrations (20 g / L, 30 g / L, 40 g / L, 50 g / L, 60 g / L) of the substrate 6-methylglycine, 0.2 mM FAD, 5% (v / v) methanol, and 50 mM PBS buffer (pH 7.0) to a final volume of 5 mL. The reaction was carried out at 40 °C and 180 rpm for 120 h. Samples of 500 µL were taken at 24, 48, 72, 96, and 120 h, and the substrate conversion rate was determined using the method in Example 2. Wild-type strain KstD2 was used as a control. Results are shown in [Figure 1]. Figure 9 and Figure 10 .
[0096] Experimental results showed that substrate concentration had a significant impact on conversion efficiency. When the substrate concentration did not exceed 40 g / L, the conversion efficiency reached 98.37% after 96 h of reaction; however, when the substrate concentration increased to 50 g / L or higher, the conversion efficiency showed a decreasing trend. This suggests that higher substrate concentrations may have a substrate inhibitory effect on enzyme activity.
[0097] like Figure 9 As shown, under the condition of substrate concentration of 40 g / L, the substrate conversion rate continuously increased with the extension of reaction time, reaching a maximum value (98.37%) at 96 h. However, when the reaction time was extended to 120 h, the conversion rate decreased slightly, which is presumably due to the feedback inhibition of enzyme activity caused by product accumulation. Therefore, 96 h was determined to be the optimal reaction time.
[0098] like Figure 10 As shown, under the condition of substrate concentration of 40 g / L, compared with wild-type cells, the transformation of mutant strains was significantly improved when samples were taken at 24 h intervals. When the transformation was 96 h, the substrate transformation rate of wild-type strain was only 28.73%, while under the same conditions, the substrate transformation rate of mutant strain KstD2-M was 98.37%, which was 3.42 times that of the original strain.
[0099] 4. Effects of enzyme on substrate catalysis and methanol on dehydrogenation reaction before and after mutation
[0100] To investigate the effects of the mutant strain and methanol on substrate solubility, four parallel reactions were set up according to strain type (the wild-type KstD2 constructed in Example 1 and the mutant KstD2-M were prepared into wet cells using the method in Example 3) and methanol addition amount (0 / 5%): Group 1: 50 g / L wild-type KstD2 wet cells, 1 mM PMS, 40 g / L substrate 6-methylglycine, 0.2 mMFAD, and 50 mM PBS (pH 7.0) buffer were added to make up to 5 mL.
[0101] Group 2: 50 g / L wild-type KstD2 wet cells, 1 mM PMS, 40 g / L substrate 6-methylglycine, 0.2 mM MFAAD, 5% methanol, and 50 mM PBS (pH 7.0) buffer to make up to 5 mL.
[0102] Group 3: 50 g / L mutant KstD2-M wet cells, 1 mM PMS, 40 g / L substrate 6-methylglycine, 0.2 mM FAD, and 50 mM PBS (pH 7.0) buffer were added to make up to 5 mL.
[0103] Group 4: 50 g / L KstD2-M mutant wet cells, 1 mM PMS, 40 g / L substrate 6-methylglycine, 0.2 mM FAD, 5% methanol, and 50 mM PBS (pH 7.0) buffer to make up to 5 mL.
[0104] Each reaction system was reacted at 40 °C and 180 rpm for 96 h. After the reaction was completed, the substrate conversion rate was detected using the method in Example 2, and the results are shown in Table 3.
[0105] Table 3: Effects of enzyme on substrate catalysis and methanol on dehydrogenation reaction before and after mutation.
[0106] As shown in Table 3, the dehydrogenation efficiency of 6-methylglycine was increased from 60.18% to 98.37% by 1.63 times through mutation and the addition of methanol to increase the solubility of the substrate. Even with the addition of methanol, the catalytic efficiency of mutant KstD2-M for 6-methylglycine was 3.42 times that of unmutated KstD2 compared with wild type.
[0107] The above description of the embodiments is intended to enable those skilled in the art to understand and use the invention. Those skilled in the art can readily make various modifications to these embodiments and apply the general principles of this description to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.
Claims
1. A 3-sterone-Δ1-dehydrogenase mutant, characterized in that, The 3-sterone-Δ1-dehydrogenase mutant was obtained by single or multiple mutations at position 156 or 165 of the amino acid sequence shown in SEQ ID NO:
1.
2. The 3-sterone-Δ1-dehydrogenase mutant as described in claim 1, characterized in that, The 3-sterone-Δ1-dehydrogenase mutant is formed by mutating the amino acid sequence shown in SEQ ID NO: 1 to one of the following: V156P, V165I, or V156P / V165I.
3. A recombinant genetically engineered bacterium expressing the encoding gene of the 3-sterone-Δ1-dehydrogenase mutant of claim 1.
4. The use of the 3-sterone-Δ1-dehydrogenase mutant of claim 1 in the production of steroidal drug intermediates.
5. The application as described in claim 4, characterized in that, The application is to catalyze the dehydrogenation of the substrate 6α-methyl-11β,17α-dihydroxy-4-pregnen-3,20-dione to synthesize 6α-methyl-11β,17α-dihydroxy-1,4-dipregnen-3,20-dione.
6. The application as described in claim 5, characterized in that, The method of application is as follows: using wet bacterial cells obtained by inducing culture of recombinant genetically engineered bacteria containing the encoding gene of 3-sterone-Δ1-dehydrogenase, or crude enzyme solution extracted by ultrasonic disruption of the wet bacterial cells, as a catalyst, using steroidal compounds as substrates, phenazine methyl sulfate as proton acceptors, flavin adenine dinucleotide as coenzymes, adding methanol as a cosolvent, and using a buffer solution of pH 6-8 as a reaction medium to construct a reaction system, reacting at 25-45℃ and 100-200 rpm for 48-120 h to obtain the dehydrogenated compound 6-methyldehydrogen.
7. The application as described in claim 6, characterized in that, In the transformation system, the substrate concentration is 20-60 g / L; the final concentration of phenazine methyl sulfate is 0.5-2.5 mM; the final concentration of flavin adenine dinucleotide is 0.2 mM; the concentration of wet bacterial cells is 30-60 g / L; and the volume percentage of methanol added is 4-5%.
8. The application as described in claim 6, characterized in that, The buffer solution is a 50 mM, pH 7.0 PBS buffer solution.
9. The application as described in claim 6, characterized in that, The wet bacterial cells were prepared as follows: recombinant genetically engineered bacteria containing the gene encoding a 3-sterone-Δ1-dehydrogenase mutant were inoculated into a solution containing 50... The seed culture was obtained by incubating the LB liquid medium containing 3 g / mL kanamycin sulfate at 37 °C and 180 rpm overnight. The seed culture was then inoculated at a volume concentration of 3% into a culture medium containing 50 g / mL kanamycin sulfate. In TB liquid medium containing g / mL kanamycin sulfate, cultured at 37 ℃ and 180 rpm until OD 600 The concentration of the enzyme was 0.6-0.
8. IPTG was added to a final concentration of 0.2 mM, and the culture was induced at 20 ℃ and 180 rpm for 16 h to obtain the fermentation broth. The fermentation broth was centrifuged at 8000 rpm and 4 ℃ for 10 min. The resulting bacterial precipitate was resuspended twice in physiological saline and centrifuged at 8000 rpm and 4 ℃ for 10 min to collect the wet bacterial cells. The wet bacterial cells were resuspended at 50 g / L in pH 7.0, 50 mM PBS buffer. The resuspended solution was placed on ice for 30 min and then sonicated. The conditions were: sonication power 360 W, sonication for 3 s, interval 7 s, sonication for 15 min. The sonicated lysate was centrifuged at 8000 rpm and 4 ℃ for 10 min and the precipitate was discarded. The resulting supernatant was the crude enzyme solution.
